NO964155L - Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger - Google Patents

Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger

Info

Publication number
NO964155L
NO964155L NO964155A NO964155A NO964155L NO 964155 L NO964155 L NO 964155L NO 964155 A NO964155 A NO 964155A NO 964155 A NO964155 A NO 964155A NO 964155 L NO964155 L NO 964155L
Authority
NO
Norway
Prior art keywords
drugs
manufacture
dysfunctional uterine
uterine bleeding
progesterone antagonists
Prior art date
Application number
NO964155A
Other languages
English (en)
Other versions
NO964155D0 (no
Inventor
Kristof Chwalsz
Klaus Stockemann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO964155L publication Critical patent/NO964155L/no
Publication of NO964155D0 publication Critical patent/NO964155D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Kompetitive progesteronantagon- ister (antigestagener) egnede for frem- stilling av legemidler til behandling av dysfunksjonelle uterusblødninger (metrorragier, menorragier, hyper- menoré).
NO964155A 1995-02-02 1996-10-01 Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger NO964155D0 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1995/000394 WO1996023503A1 (de) 1995-02-02 1995-02-02 Progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen

Publications (2)

Publication Number Publication Date
NO964155L true NO964155L (no) 1996-10-01
NO964155D0 NO964155D0 (no) 1996-10-01

Family

ID=8165951

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964155A NO964155D0 (no) 1995-02-02 1996-10-01 Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger

Country Status (20)

Country Link
US (1) US6451780B1 (no)
EP (1) EP0806952B1 (no)
JP (1) JPH10512889A (no)
KR (1) KR100370908B1 (no)
AT (1) ATE235907T1 (no)
AU (1) AU714959B2 (no)
CA (1) CA2186953C (no)
DE (1) DE59510626D1 (no)
DK (1) DK0806952T3 (no)
ES (1) ES2196063T3 (no)
FI (1) FI117850B (no)
HU (1) HU226276B1 (no)
MX (1) MX9603889A (no)
NO (1) NO964155D0 (no)
NZ (1) NZ287024A (no)
PL (1) PL316533A1 (no)
PT (1) PT806952E (no)
SK (1) SK282570B6 (no)
UA (1) UA37259C2 (no)
WO (1) WO1996023503A1 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001334T2 (tr) * 1997-11-14 2000-09-21 Akzo Nobel N.V. Progestojen-anti-progestojen rejimleri.
US8193252B1 (en) * 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
CO5200772A1 (es) 1999-08-31 2002-09-27 Jenapharm Gmbh And Co Kg Mesoprogestinas (moduladores de receptores de progesterona) para el trataiento y la prevencion de transtornos ginecolo- gicos benignos hormona-dependientes
US6685626B2 (en) 2001-02-02 2004-02-03 Regeneration Technologies, Inc. Compositions, devices, methods, and kits for induction of adhesions
US20020176893A1 (en) * 2001-02-02 2002-11-28 Wironen John F. Compositions, implants, methods, and kits for closure of lumen openings, repair of ruptured tissue, and for bulking of tissue
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
WO2005120432A1 (en) * 2004-06-07 2005-12-22 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
PT2148681E (pt) * 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
CA2872644A1 (en) 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
US11208432B2 (en) 2015-12-23 2021-12-28 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108699102A (zh) 2015-12-23 2018-10-23 欧瑞克制药公司 糖皮质激素受体抑制剂
MX385658B (es) 2016-10-07 2025-03-18 Oric Pharmaceuticals Inc Inhibidores del receptor de glucocorticoides.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622943A (en) 1992-05-06 1997-04-22 The Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding
WO1993021926A1 (en) * 1992-05-06 1993-11-11 Medical College Of Hampton Roads Minimizing progestin associated breakthrough bleeding

Also Published As

Publication number Publication date
EP0806952B1 (de) 2003-04-02
FI963049L (fi) 1996-10-01
WO1996023503A1 (de) 1996-08-08
UA37259C2 (uk) 2001-05-15
HU9602668D0 (en) 1996-11-28
KR970704451A (ko) 1997-09-06
ATE235907T1 (de) 2003-04-15
PL316533A1 (en) 1997-01-20
JPH10512889A (ja) 1998-12-08
US6451780B1 (en) 2002-09-17
DK0806952T3 (da) 2003-06-16
HU226276B1 (en) 2008-07-28
ES2196063T3 (es) 2003-12-16
KR100370908B1 (ko) 2003-04-10
CA2186953A1 (en) 1996-08-08
SK121996A3 (en) 1997-05-07
PT806952E (pt) 2003-08-29
AU714959B2 (en) 2000-01-13
CA2186953C (en) 2009-11-10
AU2561195A (en) 1996-08-21
DE59510626D1 (de) 2003-05-08
NZ287024A (en) 2001-03-30
MX9603889A (es) 1997-04-30
NO964155D0 (no) 1996-10-01
SK282570B6 (sk) 2002-10-08
EP0806952A1 (de) 1997-11-19
FI117850B (fi) 2007-03-30
FI963049A0 (fi) 1996-08-01
HUT75930A (en) 1997-05-28

Similar Documents

Publication Publication Date Title
NO964155L (no) Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger
IS6655A (is) Sýklópentanóindól, efnablöndur sem innihalda slíkefnasambönd og meðhöndlunaraðferðir
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
ATE390917T1 (de) Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
CY1105125T1 (el) Χρηση αναστολεων ακετυλοχολινεστepασης για την παρασκευη φαρμακευτικων συνθεσεων για τη θepαπευτικη αντιμετωπιση συνδρομων λειτουργικων και/ή οργανικων πονων
ATE451123T1 (de) Vaginal verabreichbare zusammensetzung zur behandlung von uteriner dysrhythmie
HK1045816A1 (zh) 角质细胞生长因子-2制剂
EA199800692A1 (ru) Изолируемые смеси из семян eugenia jambolana lamarck, способы их получения, способ получения оксамата натрия, лекарственные средства для профилактики и лечения диабета и применение указанных смесей, их компонентов и оксамата натрия для получения этих лекарственных средств
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
ATE252910T1 (de) Methode zur behandlung von fruchtbarkeitsstörungen
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
DE59511071D1 (de) Kompetitive progesteronantagonisten zur bedarfsorientierten weiblichen fertilitätskontrolle
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
IT1293804B1 (it) Diarilalchilpiperazine attive sulle basse vie urinarie
SI20852B (sl) Mezoprogestini (modulatorji receptorja progesterona) za zdravljenje in preprečevanje benignih hormonsko povzročenih ginekoloških motenj
CL2003001544A1 (es) Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
CL2003001545A1 (es) Compuestos derivados de 7,9-difluoro-5h-cromeno-[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, lei
NO20001846L (no) Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer
AR018297A1 (es) Uso de un antagonista d1/d5 para la manufactura de un medicamento para tratar desordenes compulsivos obsesivos, desordenes somatoformes, desordenesdisociativos, desordenes al comer, desordenes de control de impulso y autismo
PL356767A1 (pl) Zastosowanie hormonów płciowych do wytwarzania donosowej kompozycji farmaceutycznej, korzystnej do leczenia niepożądanych krwawień z macicy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application